Last updated: February 20, 2026
What is NDC 24208-0812?
NDC 24208-0812 corresponds to Gemin X's TG-1101 (ublituximab), an anti-CD20 monoclonal antibody used primarily for relapsing forms of multiple sclerosis (MS). It is marketed for intravenous infusion approval in the United States.
Market Size and Growth Dynamics
Therapeutic Area Overview
Gemin X's ublituximab targets B-cell depletion in MS treatment. The global MS drug market was valued at approximately USD 20 billion in 2022. The anti-CD20 class, including rituximab and ocrelizumab, dominates this space.
Market Penetration and Competitive Position
- Market entrants: Ublituximab faces competition from established therapies like ocrelizumab (Roche/Genentech), rituximab (companion to oncology), and newer agents under development.
- Market share: As a newer agent, ublituximab could capture 2-4% of the MS market within 3-5 years, assuming successful commercialization and regulatory approval.
Regional Expansion
- United States: Primary market with a potential for rapid adoption post-approval.
- Europe: Market entry depends on regulatory approval from EMA.
- Asia-Pacific: Market growth driven by increasing MS diagnoses and healthcare infrastructure development.
Pricing Landscape and Projections
Current Pricing Benchmarks
- Ocrelizumab (Ocrevus): Approximate wholesale acquisition cost (WAC) of USD 65,000 per year.
- Rituximab (off-label use): Approximate USD 20,000 to USD 40,000 per year, but often lower due to biosimilar competition.
Ublituximab Price Estimation
- Initial launch pricing: Likely to be positioned close to ocrelizumab at USD 60,000 - USD 70,000 annually.
- Cost per dose: Approximately USD 10,000 to USD 15,000, assuming a dosing schedule similar to existing anti-CD20 therapies.
Price Trajectory
| Year |
Estimated Average Price (USD) |
Rationale |
| Year 1 |
65,000 |
Competitive positioning, launch premium |
| Year 2 |
60,000–62,000 |
Competitive market pressures |
| Year 3 |
58,000–60,000 |
Entry of biosimilars, cost reduction |
| Year 4 |
55,000–58,000 |
Price adjustments, market stabilization |
Discount and Reimbursement Trends
- Reimbursement negotiations may result in net prices 10-15% lower than list prices.
- PBMs and payers favor biosimilars, which could pressure prices downward after patent expiry or biosimilar approval.
Regulatory and Commercial Risks
- Delayed approval or rejection could suppress market entry.
- Pricing pressures from biosimilars or generics substantially affect margins.
- Clinical trial outcomes influence demand and reimbursement.
Conclusion
The projected average annual price for NDC 24208-0812, pending market conditions, falls between USD 60,000 and USD 70,000 in the first three years. Market growth depends on regulatory approval, competitive dynamics, and payer acceptance.
Key Takeaways
- Ublituximab's market entry is aligned with USD 65,000 for initial pricing.
- Market share is expected to be modest initially but could grow with successful positioning.
- Price reductions are likely driven by biosimilar entry and payer negotiations.
- Regional expansion will influence overall revenue potential.
- Clinical and regulatory milestones will be decisive for future value.
FAQs
-
When is ublituximab expected to receive FDA approval?
Pending ongoing clinical trial results, targeted submission dates are in late 2023 or early 2024.
-
How does ublituximab differ from ocrelizumab?
It is a distinct monoclonal antibody with different molecular characteristics and potentially different safety or efficacy profiles.
-
What are the main competitors to ublituximab?
Ocrelizumab, rituximab, and emerging biosimilars or next-generation B-cell depletion therapies.
-
What potential cost savings can biosimilars generate?
Biosimilar versions could reduce prices by 20-40%, impacting market share and revenue.
-
How do insurance and payers influence pricing?
They negotiate rebates, tiered formulary placement, and coverage policies that impact net prices.
References
[1] Global Data. (2022). Multiple Sclerosis Market Forecasts.
[2] IQVIA. (2022). U.S. Biosimilar Market Overview.
[3] Drug Channels Institute. (2022). Pricing strategies for biologics.
[4] U.S. Food and Drug Administration. (2023). Ublituximab New Molecular Entity Application.
